Search clinical trials for: PRT-201

Total 10640 results

Ankyra Therapeutics, Inc

Recruiting

Phase I Study of ANK-101 in Advanced Solid Tumors (ANCHOR)

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Malignant Solid Tumor | Cutaneous Tumor | Subcutaneous Tumor | Metastasis to Soft Tissue

United States, Canada
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Innovo Therapeutics, Inc.

Recruiting

Ointment to Prevent Scar After Thyroidectomy

Scar

Korea, Republic of
Aardvark Therapeutics, Inc.
Children's Hospital Colorado; Stanford University

Recruiting

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Nasopharyngeal Cancer | Epstein-Barr Virus Related Carcinoma

United States
Stoke Therapeutics, Inc

Enrolling by invitation

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Dravet Syndrome

United States
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

Beta-Thalassemia

China
Blue Blood Biotech Corp.

Completed

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

Diabetic Foot Ulcer

Taiwan
Paean Biotechnology Inc.

Completed

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Dermatomyositis | Polymyositis

Korea, Republic of
MedRhythms, Inc.

Active, not recruiting

Facilitators and Barriers to the Clinical Implementation of MR-001 (RhaPSody)

Chronic Stroke

United States
Nanexa AB
CTC Clinical Trial Consultants AB

Completed

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Multiple Myeloma

Sweden
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Precigen, Inc
National Cancer Institute (NCI)

Active, not recruiting

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Papillomavirus Infections | Recurrent Respiratory Papillomatosis | Papillomaviridae

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
Dr. Anupam Sehgal
Taysha Gene Therapies, Inc.; GlycoNet

Active, not recruiting

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Infantile GM2 Gangliosidosis (Disorder)

Canada
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Immorna Biotherapeutics, Inc.

Active, not recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

United States
Invenux, LLC
State University of New York - Downstate Medical Center

Active, not recruiting

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease | Sickle-Beta Zero Thalassemia

United States
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)

GVHD,Acute
Kolon Life Science

Enrolling by invitation

A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study

Lumbosacral Radiculopathy

United States
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Arcturus Therapeutics, Inc.

Terminated

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

SARS-CoV-2

Singapore
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Reduction in Hypertrophic Skin Scarring

United States
Stargazer Pharmaceuticals, Inc.

Completed

Study of STG-001 in Subjects With Stargardt Disease

Stargardt Disease-1

United States
Andrea Wallace
Agency for Healthcare Research and Quality (AHRQ)

Completed

Social Needs Screenings in ED

Social Determinants of Health

United States
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
Tongji Hospital
Shanghai Zhongshan Hospital; Peking University Third Hospital; Huashan Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaborators

Completed

Quality Control and Evaluation in Standard COPD Management

COPD

China
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (KIDES-203)

Solid Tumours

France, Finland, Spain, Italy, Denmark, United Kingdom
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
Meir Hospital, Kfar Saba, Israel

Unknown

Assessment of Pain in Surgical Patient by PMD 200

Pain, Postoperative
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Healthpoint

Terminated

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Skin Abnormalities

United States
LivaNova

Completed

Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker (DREAM)

Bradycardia

France, Spain
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
Danube Pharmaceuticals, Inc.

Completed

Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure (DNB-001)

Ocular Hypertension | Glaucoma | Elevated IOP

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Diabetes Mellitus

China, United States, Canada, Mexico, Russian Federation, Croatia, United Kingdom, Argentina, Australia, India, South Africa, Greece, Ukraine, Romania, Italy, Hong Kong, Former Serbia and Montenegro, Brazil
Bioray Laboratories
Xiangya Hospital of Central South University; First Affiliated Hospital of... and other collaborators

Enrolling by invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

China
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
Washington University School of Medicine

Terminated

FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

Cervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

United States

Search clinical trials for: PRT-201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations